A Preliminary Study on the Bone-Targeting Potential of a New Type of Bisphosphonate in Rabbits
PAN Jun-nan1,2,CAO Gang1,2,WANG Han1,2,DENG Qi-min1,2,CHENG Zuo-yong1,2,WU Xiao-ai2,3,LI Ming-qi1,2
1. Chengdu YunKe Pharmaceutical Co.,Ltd, Chengdu 610041, China; 2. Chengdu Industry-University-Research Cooperation Laboratory of Radiopharmaceuticals,Chengdu 610041, China; 3. Department of Nuclear Medicine of West China Hospital of Sichuan University,Chengdu 610041, China
Abstract��OBJECTIVE To study the bone-targeting potential and dynamic changing process in vivo of a new type of anti-osteoporosis bisphosphonate drug under research(SC). METHODS The distribution in rabbits and bone-targeting of SC was observed by isotope tracer technique. 99Tcm-SC was injected into the rabbits, then the SPECT images were collected and analyzed in 12 h. RESULTS The labeling rate of 99Tcm-SC could be maintained above 90% within 12 h, which proved the good stability of 99Tcm-SC in vitro. The rabbit bone imaging showed that the targeting of SC to bone was equivalent to MDP, a bone imaging agent. CONCLUSION This study provides valuable data for the non-clinical and clinical studies of SC. SC has a good potential for being developed into a new generation of anti-osteoporosis drug.
�˿��У��ܸգ����������������ã���С����������. һ�����Ͷ������ҩ����ùǰ����Գ����о�[J]. �й�ҩѧ��־, 2016, 51(20): 1771-1775.
PAN Jun-nan,CAO Gang,WANG Han,DENG Qi-min,CHENG Zuo-yong,WU Xiao-ai,LI Ming-qi. A Preliminary Study on the Bone-Targeting Potential of a New Type of Bisphosphonate in Rabbits. Chinese Pharmaceutical Journal, 2016, 51(20): 1771-1775.
LIU Z Y,LI Z R. Advances in osteoporosis therapy. Chin Pharm J(�й�ҩѧ��־),2006,41(10):721-725.
[2]
HE J H,TONG N W,LI H Q,et al. Effects of L-threonate on bone resorption by osteoclasts in vitro. J Sichuan Univ(�Ĵ���ѧѧ��),2005,36(2):225-228.
[3]
LI S X,WANG Z Q,HU W X,et al. Research progress of bisphosphonate for treatment and prevention of postmenopausal osteoporosis. Chin Pharm J(�й�ҩѧ��־),1997,32(2):65-68.
[4]
ODVINA C V,ZERWEKH J E,RAO D S,et al. Severely suppressed bone turnover:a potential complication of alendronate therapy. J Clin Endocrinol Metab,2005,90(3):1294-1301.
[5]
HUANG J Q,FU D X, SUN C H. ADRs Induced by diphosphonate and notice in the application of diphosphonate. Eval Anal Drug Use Hosp China(�й�ҽԺ��ҩ���������),2008,8(5):325-327.
[6]
MAGGIO D,BARABANI M,PIERANDREI M,et al. Marked decrease in plasma antioxidants in aged osteoporotic women:results of a cross-sectional study. J Clin Endocrinol Metab,2003,88(4):1523-1527.
[7]
ALTINDAG O,EREL O,SORAN N,et al. Total oxidative/anti-oxidative status and relation to bone mineral density in osteoporosis. Rheumatol Int,2008,28(4):317-321.
[8]
LI M Q,WANG H,DENG Q M, et al. A bisphosphonate compound and preparation methods:China,CN102453050A. 2012-05-16.
[9]
QIAN M L,MA Y,WANG P M,et al. Research progress of bisphosphonates as bone targeted carrier for treatment of common bone disease. J Emerg Tradit Chin Med(�й���ҽ��֢),2010,19(3):498-499. PIERCE W M, LEONARD W C. Bone-targeted inhibitors of carbonic anhydrase:USA,EP201057. 1986-11-12. GU J J,DENG Y J.progress on bone-targeting drugs and related carriers. Chin J Pharm(�й�ҩ��ѧ��־),2009,7(3):191-197. ZHAI H Z,LUO S N,WANG Y,et al. Synthesis of M4IDP and Optimum Labeling Conditions of 99Tcm-M4IDP. J Isotop(ͬλ��),2010,23(4):225-229. WIDLER L,JAEGGI K A,GLATT M,et al. Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa). J Med Chem,2002,45(17):3721-3738. MORENO-REYES R, EGRISE D, NEVE J,et al. Selenium deficiency-induced growth retardation is associated with an impaired bone metabolism and osteopenia. J Bone Miner Res, 2001, 16(8):1556-1563. TURAN B,CAN B,DELILBASI E. Selenium combined with vitamin E and vitamin C restores structural alterations of bones in heparin-induced osteoporosis. J Clin Rheumatol,2003,22(6):432-436. FANG Y,PENG Q W. Progress on the methods of targeted evaluation of pharmaceutical preparations. China Pharm(�й�ҩʦ),2013,16(8):1232-1234.
2016, Vol. 51 
